BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 11269779)

  • 1. Increased autoantibodies against oxidized low-density lipoprotein in coronary circulation in patients with coronary spastic angina.
    Ogawa H; Soejima H; Takazoe K; Miyamoto S; Kajiwara I; Shimomura H; Sakamoto T; Yoshimura M; Kugiyama K; Kimura M; Yasue H
    Angiology; 2001 Mar; 52(3):167-74. PubMed ID: 11269779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increase in plasma levels of oxidized low-density lipoproteins in patients with coronary spastic angina.
    Kugiyama K; Sugiyama S; Soejima H; Kawano H; Sakamoto T; Takazoe K; Ogawa H; Doi H; Yasue H
    Atherosclerosis; 2001 Feb; 154(2):463-7. PubMed ID: 11166780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autoantibodies to oxidized low density lipoprotein: the relationship to low density lipoprotein fatty acid composition in diabetes.
    Griffin ME; McInerney D; Fraser A; Johnson AH; Collins PB; Owens D; Tomkin GH
    Diabet Med; 1997 Sep; 14(9):741-7. PubMed ID: 9300223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of autoantibodies against oxidized low-density lipoproteins and of IgG-bound low density lipoproteins in patients with coronary artery disease.
    Boullier A; Hamon M; Walters-Laporte E; Martin-Nizart F; Mackereel R; Fruchart JC; Bertrand M; Duriez P
    Clin Chim Acta; 1995 Jun; 238(1):1-10. PubMed ID: 7554289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Formation of platelet aggregates after attacks of coronary spastic angina pectoris.
    Miyamoto S; Ogawa H; Soejima H; Takazoe K; Sakamoto T; Yoshimura M; Kugiyama K; Yasue H
    Am J Cardiol; 2000 Feb; 85(4):494-7, A10. PubMed ID: 10728958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Presence of autoantibodies against oxidatively modified low-density lipoprotein in essential hypertension: a biochemical signature of an enhanced in vivo low-density lipoprotein oxidation.
    Maggi E; Marchesi E; Ravetta V; Martignoni A; Finardi G; Bellomo G
    J Hypertens; 1995 Jan; 13(1):129-38. PubMed ID: 7759843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized low-density lipoprotein.
    Tsimikas S; Lau HK; Han KR; Shortal B; Miller ER; Segev A; Curtiss LK; Witztum JL; Strauss BH
    Circulation; 2004 Jun; 109(25):3164-70. PubMed ID: 15184281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autoantibody against, malondialdehyde-modified low density lipoprotein in patients with non-diabetic unstable angina: a potential role in immunologic reaction of plaque instability.
    Kwon KH; Kwon HM; Hong BK; Kim DS; Lee JY; Ryu SK; Park BE; Park HY; Kim JH; Yoon YW; Cho SY; Kim HS
    Yonsei Med J; 2002 Apr; 43(2):203-10. PubMed ID: 11971214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The low-density lipoprotein (LDL)-associated PAF-acetylhydrolase activity and the extent of LDL oxidation are important determinants of the autoantibody titers against oxidized LDL in patients with coronary artery disease.
    Lourida ES; Papathanasiou AI; Goudevenos JA; Tselepis AD
    Prostaglandins Leukot Essent Fatty Acids; 2006 Aug; 75(2):117-26. PubMed ID: 16843649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autoantibodies to malondialdehyde-modified low-density lipoprotein in patients with angiographically confirmed coronary artery disease.
    McDowell A; Young IS; Wisdom GB
    J Pharm Pharmacol; 2002 Dec; 54(12):1651-7. PubMed ID: 12542895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased levels of autoantibodies against copper-oxidized low density lipoprotein, malondialdehyde-modified low density lipoprotein and cardiolipin in patients with rheumatoid arthritis.
    Cvetkovic JT; Wållberg-Jonsson S; Ahmed E; Rantapää-Dahlqvist S; Lefvert AK
    Rheumatology (Oxford); 2002 Sep; 41(9):988-95. PubMed ID: 12209031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating oxidized low density lipoprotein, autoantibodies against them and homocysteine serum levels in diagnosis and estimation of severity of coronary artery disease.
    Faviou E; Vourli G; Nounopoulos C; Zachari A; Dionyssiou-Asteriou A
    Free Radic Res; 2005 Apr; 39(4):419-29. PubMed ID: 16028367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum autoantibodies against human oxidized low-density lipoproteins are inversely associated with severity of coronary stenotic lesions calculated by Gensini score.
    Che J; Li G; Wang W; Li Q; Liu H; Chen K; Liu T
    Cardiol J; 2011; 18(4):364-70. PubMed ID: 21769816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heritability of Biomarkers of Oxidized Lipoproteins: Twin Pair Study.
    Rao F; Schork AJ; Maihofer AX; Nievergelt CM; Marcovina SM; Miller ER; Witztum JL; O'Connor DT; Tsimikas S
    Arterioscler Thromb Vasc Biol; 2015 Jul; 35(7):1704-11. PubMed ID: 25953646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autoantibodies against MDA-LDL in subjects with severe and minor atherosclerosis and healthy population controls.
    van de Vijver LP; Steyger R; van Poppel G; Boer JM; Kruijssen DA; Seidell JC; Princen HM
    Atherosclerosis; 1996 May; 122(2):245-53. PubMed ID: 8769687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autoantibodies against oxidized low-density lipoprotein and C-reactive protein are associated with diabetes and myocardial infarction in women.
    Dotevall A; Hulthe J; Rosengren A; Wiklund O; Wilhelmsen L
    Clin Sci (Lond); 2001 Nov; 101(5):523-31. PubMed ID: 11672458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of low-density lipoprotein (LDL) antigen source on an enzyme-linked immunosorbent assay for autoantibodies against oxidized LDL.
    Craig WY; Raytcheva SE; Poulin SE; Ritchie RF
    Ann Clin Biochem; 1999 May; 36 ( Pt 3)():333-9. PubMed ID: 10376075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diffuse disorder of coronary artery vasomotility in patients with coronary spastic angina. Hyperreactivity to the constrictor effects of acetylcholine and the dilator effects of nitroglycerin.
    Okumura K; Yasue H; Matsuyama K; Ogawa H; Kugiyama K; Ishizaka H; Sumida H; Fujii H; Matsunaga T; Tsunoda R
    J Am Coll Cardiol; 1996 Jan; 27(1):45-52. PubMed ID: 8522709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of plasma level of malondialdehyde-modified low-density lipoprotein with coronary plaque morphology in patients with coronary spastic angina: implication of acute coronary events.
    Tani S; Nagao K; Anazawa T; Kawamata H; Furuya S; Fuji T; Takahashi H; Iida K; Matsumoto M; Kumabe T; Sato Y; Hirayama A
    Int J Cardiol; 2009 Jun; 135(2):202-6. PubMed ID: 18614250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationships between serum levels of autoantibodies against oxidized low density lipoproteins, lipid-soluble antioxidants and apolipoprotein B in patients with coronary heart disease.
    Bakalova RA; Hadzhimitova V; Ribarov S
    Gen Physiol Biophys; 2000 Mar; 19(1):103-13. PubMed ID: 10930142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.